Abstracts tagged "Interferons and rheumatoid arthritis"

Abstract Number: 1032 • 2016 ACR/ARHP Annual Meeting
Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis
Katarzyna Matyja^1,2, Matthieu Ribon^1,2, Roxane Hervé^1,2, Delphine Lemeiter^1,2, Ken Tsumiyama³, Natacha Bessis^1,2, Shunichi Shiozawa³, Marie-Christophe Boissier^1,2,4 and Patrice Decker^1,2, ¹Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²UMR 1125, Inserm, Bobigny, France, ³Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France
Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
Abstract Number: 2723 • 2015 ACR/ARHP Annual Meeting
Basal STAT5 Signaling Is Elevated in Multiple Peripheral Blood Cell Subsets in Rheumatoid Arthritis and Is Markedly Downregulated By IFN-Î³ in T Lymphocytes
Molly Boland¹, Yanna Ding², Surabhi Vinod³, S. Louis Bridges Jr.⁴ and Chander Raman¹, ¹Medicine/Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Medicine/Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The importance of type I interferons (IFN-α and others) as a driver of pathogenesis in autoimmunity, including rheumatoid arthritis (RA) is well recognized. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].